Review
Copyright ©The Author(s) 2015.
World J Respirol. Jul 28, 2015; 5(2): 112-125
Published online Jul 28, 2015. doi: 10.5320/wjr.v5.i2.112
Table 1 An overview of the futures of the three adaptive servo-ventilation devices
ManufacturerResMedPhilips-RespironicsWeinmann
Current versionS9 VPAP Adapt, AutoSet CS-ABiPAP autoSV Advanced System OnePrisma LINE CR
EPAP (default)4-15 cmH2O auto4-15 cmH2O auto4-20 cmH2O auto
(min EPAP)4-15 cmH2O4-25 cmH2O4-20 cmH2O
(max EPAP)min EPAP-15 cmH2Omin EPAP-25 cmH2Omin EPAP-20 cmH2O
IPAPMax 30 cmH2OMax 25 cmH2OMax 30 cmH2O
PS0 to 30-prevailing EPAP0 to 25-prevailing EPAP0 to 30-prevailing EPAP
CalculationThe recent 3-min average minute volumeThe recent 4-min average peak flowThe average of the minute volume in the recent 2-min and an earlier interval
Target for PS90% of the average minute volume90%-95% of the average peak flow (without SDB)Relative minute volume of the current breath to the average
60% percentile of peak flow (with SDB)
Approximate the minute volume to the targetApproximate the peak inspiratory flow to the targetStabilize the relative minute volume
Backup rateAuto (cannot be established manually)Auto (default) or fixed rateAuto (default) or fixed rate
Table 2 Clinical trials assessing the effects of adaptive-servo ventilation on cardiac function in heart failure patients with central sleep apnea
Ref.Study designnDuration (mo)Baseline
Device usage (h)Changes
AHIEFAHIEF
Pepperell et al[36]RCT
Subtherapeutic15117.735.73.9-30.5
Therapeutic1521.936.55.0-16.51.8
Philippe et al[3]RCT
CPAP13640.530.04.2-20-2
ASV1247.029.05.8-457
Fietze et al[37]RCT
Bi-level PAP151.534.925.54.81-18.55.6
ASV1531.724.6-20.51.9
1Kasai et al[4]RCT
CPAP-mode11323.0233.03.30.1-1
ASV-mode1225.0232.04.7-235.8
Table 3 Clinical trials assessing the effects of adaptive-servo ventilation on cardiac function in heart failure patients with central sleep apnea and coexisting obstructive sleep apnea
Ref.Study designnDuration (mo)Baseline
Device usage (h)Changes
AHIEFAHIEF
Kasai et al[40]RCT
CPAP15338.6364.4-23.21.9
f-ASV1636.335.75.25-35.49.1
Randerath et al[41]RCT
CPAP341241434.3-24.04.9
f-ASV3647475.2-36.0-1.9
Yoshihisa et al[42]RCT
Control1863654--8.2-2.0
v-ASV183756.15.6-30.25.1
Birner et al[43]RCT
Control3534329-03.0
f-ASV3752304.2-41.01.0
Table 4 Summary of recommendations for the use of adaptive-servo ventilation in various settings
SettingsIndicationImprovement other than AHISupporting evidence
With SDB
HFAfter optimization of HF, with CSA not suppressed by CPAPDaytime sleepinessRCTs (vs CPAP)[3,4,40,41,43]
LVEFRCTs (vs control)[36,42]
BNPRCT (vs Bi-level PAP)[37]
Event-free survival
Treatment-emergent CSAWith HFSame as HF
Without HFSleep architectureRetrospective studies (pre-post study, vs CPAP)[64,65]
Adherence of PAP
Idiopathic CSAWith symptomsDaytime alertness and moodCase series (pre-post study, vs CPAP or oxygen)[5]
Opioid-induced CSABenefit unknown
Stroke-related CSAPost-acute phaseDaytime sleepinessA single-center retrospective study (pre-post study)[86]
Without SDB
HFRegardless of the presence or absence of SDBLVEFA multi-center retrospective study (pre-post study)[91]
NYHA class
Acute cardiogenic pulmonary edemaWith elevated filling pressureDyspneaAn observational study (vs supplemental oxygen alone)[12]
High blood pressure
Atrial fibrillationDuring PVIProcedural timeOn-off study[93]